Norges Bank’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,074,936
| Closed | -$138M | – | 236 |
|
|
2025
Q2 | $138M | Buy |
1,074,936
+472,009
| +78% | +$49M | 0.02% | 591 |
|
|
2025
Q1 | $53.4M | Sell |
602,927
-108,237
| -15% | -$10.6M | 0.01% | 910 |
|
|
2024
Q4 | $62M | Buy |
711,164
+107,935
| +18% | +$9.89M | 0.01% | 880 |
|
|
2024
Q3 | $55.8M | Buy |
603,229
+11,103
| +2% | +$1.1M | 0.01% | 927 |
|
|
2024
Q2 | $63.8M | Buy |
592,126
+23,961
| +4% | +$2.4M | 0.01% | 807 |
|
|
2024
Q1 | $53.9M | Sell |
568,165
-37,786
| -6% | -$3.24M | 0.01% | 902 |
|
|
2023
Q4 | $55.9M | Buy |
605,951
+19,955
| +3% | +$1.29M | 0.01% | 852 |
|
|
2023
Q3 | $29.4M | Buy |
585,996
+12,810
| +2% | +$685K | 0.01% | 1069 |
|
|
2023
Q2 | $36.2M | Buy |
573,186
+12,394
| +2% | +$674K | 0.01% | 1012 |
|
|
2023
Q1 | $25.2M | Sell |
560,792
-73,253
| -12% | -$3.3M | 0.01% | 1170 |
|
|
2022
Q4 | $27.8M | Sell |
634,045
-156,910
| -20% | -$7.52M | 0.01% | 1118 |
|
|
2022
Q3 | $52.1M | Buy |
790,955
+176,054
| +29% | +$11.3M | 0.01% | 744 |
|
|
2022
Q2 | $31.1M | Sell |
614,901
-203,556
| -25% | -$11.9M | 0.01% | 1013 |
|
|
2022
Q1 | $52.3M | Buy |
818,457
+12,269
| +2% | +$881K | 0.01% | 856 |
|
|
2021
Q4 | $86.4M | Buy |
806,188
+69,031
| +9% | +$7.22M | 0.02% | 675 |
|
|
2021
Q3 | $75.8M | Buy |
737,157
+64,184
| +10% | +$5.98M | 0.02% | 731 |
|
|
2021
Q2 | $59.2M | Sell |
672,973
-36,935
| -5% | -$3.38M | 0.01% | 874 |
|
|
2021
Q1 | $69M | Sell |
709,908
-70,356
| -9% | -$7.02M | 0.02% | 791 |
|
|
2020
Q4 | $87.5M | Sell |
780,264
-199,050
| -20% | -$21M | 0.02% | 647 |
|
|
2020
Q3 | $90.8M | Sell |
979,314
-177,357
| -15% | -$13.7M | 0.02% | 578 |
|
|
2020
Q2 | $90.2M | Sell |
1,156,671
-413,141
| -26% | -$27.9M | 0.03% | 543 |
|
|
2020
Q1 | $91.8M | Buy |
1,569,812
+572,200
| +57% | +$36.8M | 0.03% | 459 |
|
|
2019
Q4 | $79.9M | Buy |
997,612
+265,400
| +36% | +$19.9M | 0.02% | 650 |
|
|
2019
Q3 | $53.8M | Sell |
732,212
-43,332
| -6% | -$3.75M | 0.02% | 824 |
|
|
2019
Q2 | $73.2M | Sell |
775,544
-120,000
| -13% | -$9.9M | 0.02% | 663 |
|
|
2019
Q1 | $71.7M | Buy |
895,544
+103,393
| +13% | +$7.64M | 0.02% | 638 |
|
|
2018
Q4 | $42.7M | Hold |
792,151
| – | – | 0.02% | 852 |
|
|
2018
Q3 | $61.8M | Sell |
792,151
-135,182
| -15% | -$9.4M | 0.02% | 716 |
|
|
2018
Q2 | $58.9M | Buy |
927,333
+115,581
| +14% | +$9.2M | 0.02% | 724 |
|
|
2018
Q1 | $74.4M | Buy |
811,752
+35,018
| +5% | +$3.02M | 0.03% | 593 |
|
|
2017
Q4 | $58.6M | Buy |
776,734
+313,039
| +68% | +$22M | 0.02% | 705 |
|
|
2017
Q3 | $32.3M | Buy |
463,695
+88,695
| +24% | +$4.74M | 0.01% | 1100 |
|
|
2017
Q2 | $19M | Buy |
+375,000
| New | +$15.9M | 0.01% | 1444 |
|
|
2017
Q1 | – | Sell |
-25,000
| Closed | -$701K | – | 2143 |
|
|
2016
Q4 | $701K | Buy |
+25,000
| New | +$753K | ﹤0.01% | 2096 |
|
|
2015
Q3 | – | Sell |
-20,000
| Closed | -$530K | – | 2288 |
|
|
2015
Q2 | $530K | Buy |
+20,000
| New | +$571K | ﹤0.01% | 2183 |
|
Other funds holding BPMC
IA
HNB
Norges Bank's BPMC Position: Q3 2025 in Review
Norges Bank sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,074,936 shares — an estimated $138M sold.
Norges Bank first reported a position in BPMC in Q2 2015 and held it in 35 quarters. The position peaked at $138M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Norges Bank reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Norges Bank sold 1,074,936 Blueprint Medicines shares in Q3 2025, an estimated $138M.
- Norges Bank first reported a position in Blueprint Medicines in Q2 2015 and held it in 35 quarters.
- Norges Bank's Blueprint Medicines position peaked at $138M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Norges Bank's 13F filing for Q3 2025.